NO330872B1 - Utvortes preparat for behandling av pruritus - Google Patents
Utvortes preparat for behandling av pruritus Download PDFInfo
- Publication number
- NO330872B1 NO330872B1 NO20023111A NO20023111A NO330872B1 NO 330872 B1 NO330872 B1 NO 330872B1 NO 20023111 A NO20023111 A NO 20023111A NO 20023111 A NO20023111 A NO 20023111A NO 330872 B1 NO330872 B1 NO 330872B1
- Authority
- NO
- Norway
- Prior art keywords
- pruritus
- preparation
- preparations
- itching
- aspirin
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 56
- 208000003251 Pruritus Diseases 0.000 title claims description 44
- 238000011282 treatment Methods 0.000 title claims description 12
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 39
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 39
- 230000007803 itching Effects 0.000 claims description 24
- 239000002674 ointment Substances 0.000 claims description 18
- 208000010668 atopic eczema Diseases 0.000 claims description 13
- 201000008937 atopic dermatitis Diseases 0.000 claims description 11
- 201000004624 Dermatitis Diseases 0.000 claims description 9
- 208000006877 Insect Bites and Stings Diseases 0.000 claims description 9
- 230000002500 effect on skin Effects 0.000 claims description 8
- 239000006210 lotion Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 206010012442 Dermatitis contact Diseases 0.000 claims description 4
- 208000024780 Urticaria Diseases 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 4
- 208000010247 contact dermatitis Diseases 0.000 claims description 4
- 230000037380 skin damage Effects 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 208000037157 Azotemia Diseases 0.000 claims description 3
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims description 3
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 3
- 206010039986 Senile pruritus Diseases 0.000 claims description 3
- 208000002847 Surgical Wound Diseases 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 230000002124 endocrine Effects 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- 208000009852 uremia Diseases 0.000 claims description 3
- -1 yellow vaseline Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 235000014113 dietary fatty acids Nutrition 0.000 description 12
- 239000000194 fatty acid Substances 0.000 description 12
- 229930195729 fatty acid Natural products 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 12
- 239000000499 gel Substances 0.000 description 11
- 230000001139 anti-pruritic effect Effects 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 239000002585 base Substances 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 150000003431 steroids Chemical class 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 description 6
- 239000000945 filler Substances 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 206010012434 Dermatitis allergic Diseases 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 5
- 210000004100 adrenal gland Anatomy 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000003883 ointment base Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 239000005642 Oleic acid Substances 0.000 description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 239000000739 antihistaminic agent Substances 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
- 235000019271 petrolatum Nutrition 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 3
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- 239000004264 Petrolatum Substances 0.000 description 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000001387 anti-histamine Effects 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 229940064004 antiseptic throat preparations Drugs 0.000 description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 3
- 229960003338 crotamiton Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229940074928 isopropyl myristate Drugs 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229940066842 petrolatum Drugs 0.000 description 3
- 239000011505 plaster Substances 0.000 description 3
- 239000004584 polyacrylic acid Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- 239000003871 white petrolatum Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- COPFWAGBXIWZNK-UHFFFAOYSA-N 2,3-bis(6-methylheptanoyloxy)propyl 6-methylheptanoate Chemical compound CC(C)CCCCC(=O)OCC(OC(=O)CCCCC(C)C)COC(=O)CCCCC(C)C COPFWAGBXIWZNK-UHFFFAOYSA-N 0.000 description 2
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 2
- 239000004925 Acrylic resin Substances 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 2
- 239000013032 Hydrocarbon resin Substances 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 239000003908 antipruritic agent Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940031578 diisopropyl adipate Drugs 0.000 description 2
- 229940031569 diisopropyl sebacate Drugs 0.000 description 2
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229940100463 hexyl laurate Drugs 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 229920006270 hydrocarbon resin Polymers 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000004898 kneading Methods 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 2
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 150000003611 tocopherol derivatives Chemical class 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 229940103272 aluminum potassium sulfate Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940015826 dihydroxyaluminum aminoacetate Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Prostheses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP37354799 | 1999-12-28 | ||
| PCT/JP2000/008888 WO2001047525A1 (fr) | 1999-12-28 | 2000-12-15 | Agent antipruritique a usage externe |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20023111D0 NO20023111D0 (no) | 2002-06-27 |
| NO20023111L NO20023111L (no) | 2002-06-27 |
| NO330872B1 true NO330872B1 (no) | 2011-08-01 |
Family
ID=18502352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20023111A NO330872B1 (no) | 1999-12-28 | 2002-06-27 | Utvortes preparat for behandling av pruritus |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20030125308A1 (fr) |
| EP (1) | EP1249239B1 (fr) |
| JP (1) | JP4813725B2 (fr) |
| KR (1) | KR20020068385A (fr) |
| CN (1) | CN1414856A (fr) |
| AT (1) | ATE395920T1 (fr) |
| AU (1) | AU779590B2 (fr) |
| CA (1) | CA2394471C (fr) |
| DE (1) | DE60038979D1 (fr) |
| ES (1) | ES2304989T3 (fr) |
| HU (1) | HU228233B1 (fr) |
| IL (2) | IL150121A0 (fr) |
| MX (1) | MXPA02006447A (fr) |
| NO (1) | NO330872B1 (fr) |
| NZ (1) | NZ519783A (fr) |
| WO (1) | WO2001047525A1 (fr) |
| ZA (1) | ZA200204624B (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4868687B2 (ja) * | 2002-09-30 | 2012-02-01 | 帝國製薬株式会社 | ケロイド等の形成抑制外用剤 |
| JP4791682B2 (ja) * | 2003-02-21 | 2011-10-12 | 帝國製薬株式会社 | 痔疾患用治療剤 |
| JP2004262776A (ja) * | 2003-02-21 | 2004-09-24 | Teikoku Seiyaku Co Ltd | 血管新生促進剤 |
| BRPI0418547A (pt) * | 2004-02-16 | 2007-05-22 | Teikoku Seiyaku Kk | preparação externa para tratamento de danos da pele ou da mucosa causados por infecção viral. |
| AU2004315561B2 (en) * | 2004-02-16 | 2010-10-28 | Teikoku Seiyaku Co., Ltd. | External preparation for treating painful skin wound |
| EP1656935A1 (fr) * | 2004-11-12 | 2006-05-17 | Cognis IP Management GmbH | Utilisation des acides gras physiologiquement actifs pour le traitement du prurit |
| CN101380317B (zh) * | 2007-09-07 | 2010-12-08 | 英属开曼群岛商安盛开发药物股份有限公司 | 减缓搔痒症的药学组合物 |
| WO2009075094A1 (fr) * | 2007-12-11 | 2009-06-18 | Medrx Co., Ltd. | Préparation de ruban adhésif comportant de l'étodolac sous forme de liquide ionique |
| JP2010120912A (ja) * | 2008-11-21 | 2010-06-03 | Lead Chemical Co Ltd | ５−メチル−１−フェニル−２−（１ｈ）−ピリドン含有貼付剤 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4126681A (en) * | 1975-12-08 | 1978-11-21 | The Procter & Gamble Company | Topical composition containing acetyl salicylic acid |
| US4032662A (en) * | 1976-01-05 | 1977-06-28 | Idabelle K. Mannear | Method for the treatment of contact allergic dermatitis |
| US4219548A (en) * | 1978-09-01 | 1980-08-26 | The Procter & Gamble Company | Topical anti-inflammatory composition |
| US4395420A (en) * | 1981-12-09 | 1983-07-26 | Bernstein Joel E | Method and composition for treating pruritis |
| US4822604A (en) * | 1985-05-20 | 1989-04-18 | S. C. Johnson & Son, Inc. | Local treatment of dandruff, seborrheic dermatitis, and psoriasis |
| US4797402A (en) * | 1987-06-02 | 1989-01-10 | Dorsey Kenneth E | Cooling anti-itch skin preparations |
| JPS6429315A (en) * | 1987-07-23 | 1989-01-31 | Tokyo Medeitsuku Kk | Drug for athlete's foot |
| US4975269A (en) * | 1989-07-31 | 1990-12-04 | Leonard Chavkin | Shelf stable aspirin solutions |
| JP2501671B2 (ja) * | 1991-02-04 | 1996-05-29 | 救急薬品工業株式会社 | 高放出性鎮痒貼付剤 |
| GB9104286D0 (en) * | 1991-02-28 | 1991-04-17 | Phytopharm Ltd | Pharmaceutical compositions for the treatment of skin disorders |
| US5240917A (en) * | 1991-04-03 | 1993-08-31 | Keimowitz Rudolph M | Suppression of thromboxane levels by percutaneous administration of aspirin |
| JPH05286860A (ja) * | 1992-04-03 | 1993-11-02 | Kowa Co | ゲル軟膏剤 |
| EP0885611A3 (fr) * | 1992-09-24 | 1999-01-07 | Sepracor, Inc. | Procédés et compositions pour traiter des affections allergiques à l'aide de (+)cetirizine optiquement pure |
| US6300326B1 (en) * | 1994-11-02 | 2001-10-09 | Michael R. Dobbs | Composition and method for control and treatment of cutaneous inflammation |
| ATE249819T1 (de) * | 1995-04-21 | 2003-10-15 | Seikisui Chemical Co Ltd | Präparate zur äusserlichen anwendung zur behandlung von dermatosen |
| US5776920A (en) * | 1995-08-02 | 1998-07-07 | Quarles; Ruth | Method for treatment of psoriasis |
| US5932230A (en) * | 1997-05-20 | 1999-08-03 | Degrate; Frenchell | Topical analgesic formulation containing fruits, oils and aspirin |
| US6372234B1 (en) * | 1997-05-27 | 2002-04-16 | Sembiosys Genetics Inc. | Products for topical applications comprising oil bodies |
| JPH1112177A (ja) * | 1997-06-25 | 1999-01-19 | Teikoku Seiyaku Co Ltd | 安定なアスピリン含有外用製剤 |
| KR20000076105A (ko) * | 1998-01-13 | 2000-12-26 | 도리이 신이찌로 | 항생제를 함유한 국소 투여용 항균 조성물 |
| US6423343B1 (en) * | 1998-01-23 | 2002-07-23 | Usbiomaterials Corporation | Bioactive glass treatment of inflammation in skin conditions |
| US6960579B1 (en) * | 1998-05-19 | 2005-11-01 | Alcon Manufacturing, Ltd. | Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders |
| US7056893B2 (en) * | 1999-03-31 | 2006-06-06 | Insite Vision, Inc. | Topical treatment for prevention of ocular infections |
| US6177413B1 (en) * | 2000-03-03 | 2001-01-23 | Natalie Blahut | Stabilized aspirin compositions and method of preparation for oral and topical use |
| AU2001245891A1 (en) * | 2000-03-21 | 2001-10-03 | The Procter & Gamble Company | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors |
| WO2002083743A1 (fr) * | 2001-04-16 | 2002-10-24 | Wsp Chemicals & Technology Llc | Complexes polymeriques hydrosolubles |
| JP2004536854A (ja) * | 2001-07-18 | 2004-12-09 | ユニリーバー・ナームローゼ・ベンノートシヤープ | 頭髪及び／または頭皮のトリートメント組成物 |
| EP1499339A4 (fr) * | 2002-04-12 | 2008-04-02 | Univ Yale | Effets de cicatrisation de blessure et anti-inflammatoires de la thymosine beta 4 lymphoide |
| US6900224B2 (en) * | 2002-07-31 | 2005-05-31 | The Procter & Gamble Company | Antimicrobial quinolones, their compositions and uses |
| DE10256629B3 (de) * | 2002-12-03 | 2004-02-19 | Schott Glas | Vorzugsweise Pb- und As-freie optische Gläser mit Tg ≦ 500°C und deren Verwendung |
| US20060275230A1 (en) * | 2004-12-10 | 2006-12-07 | Frank Kochinke | Compositions and methods for treating conditions of the nail unit |
| CA2602341A1 (fr) * | 2005-03-23 | 2006-09-28 | Elan Pharma International Limited | Formulations d'un corticosteroide nanoparticulaire et d'un antihistamine |
| US20070110739A1 (en) * | 2005-11-11 | 2007-05-17 | Logsdon Lawrence M | Wipe away pain |
-
2000
- 2000-12-15 CA CA2394471A patent/CA2394471C/fr not_active Expired - Fee Related
- 2000-12-15 MX MXPA02006447A patent/MXPA02006447A/es active IP Right Grant
- 2000-12-15 KR KR1020027008214A patent/KR20020068385A/ko active Search and Examination
- 2000-12-15 AT AT00981741T patent/ATE395920T1/de not_active IP Right Cessation
- 2000-12-15 US US10/169,200 patent/US20030125308A1/en not_active Abandoned
- 2000-12-15 AU AU18907/01A patent/AU779590B2/en not_active Ceased
- 2000-12-15 ES ES00981741T patent/ES2304989T3/es not_active Expired - Lifetime
- 2000-12-15 CN CN00817978A patent/CN1414856A/zh active Pending
- 2000-12-15 IL IL15012100A patent/IL150121A0/xx unknown
- 2000-12-15 DE DE60038979T patent/DE60038979D1/de not_active Expired - Lifetime
- 2000-12-15 JP JP2001548119A patent/JP4813725B2/ja not_active Expired - Fee Related
- 2000-12-15 EP EP00981741A patent/EP1249239B1/fr not_active Expired - Lifetime
- 2000-12-15 NZ NZ519783A patent/NZ519783A/en not_active IP Right Cessation
- 2000-12-15 HU HU0204208A patent/HU228233B1/hu not_active IP Right Cessation
- 2000-12-15 WO PCT/JP2000/008888 patent/WO2001047525A1/fr active IP Right Grant
-
2002
- 2002-06-09 IL IL150121A patent/IL150121A/en not_active IP Right Cessation
- 2002-06-10 ZA ZA200204624A patent/ZA200204624B/en unknown
- 2002-06-27 NO NO20023111A patent/NO330872B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0204208A3 (en) | 2003-04-28 |
| AU1890701A (en) | 2001-07-09 |
| NO20023111D0 (no) | 2002-06-27 |
| EP1249239A1 (fr) | 2002-10-16 |
| DE60038979D1 (de) | 2008-07-03 |
| IL150121A0 (en) | 2002-12-01 |
| MXPA02006447A (es) | 2003-09-22 |
| KR20020068385A (ko) | 2002-08-27 |
| CA2394471C (fr) | 2010-05-25 |
| ZA200204624B (en) | 2003-01-22 |
| WO2001047525A1 (fr) | 2001-07-05 |
| HU228233B1 (en) | 2013-02-28 |
| EP1249239A4 (fr) | 2006-04-05 |
| IL150121A (en) | 2009-07-20 |
| ES2304989T3 (es) | 2008-11-01 |
| CA2394471A1 (fr) | 2001-07-05 |
| JP4813725B2 (ja) | 2011-11-09 |
| CN1414856A (zh) | 2003-04-30 |
| ATE395920T1 (de) | 2008-06-15 |
| US20030125308A1 (en) | 2003-07-03 |
| NZ519783A (en) | 2005-05-27 |
| NO20023111L (no) | 2002-06-27 |
| AU779590B2 (en) | 2005-02-03 |
| HUP0204208A2 (hu) | 2003-03-28 |
| EP1249239B1 (fr) | 2008-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2727155C (fr) | Preparation dermatologique renfermant de l'oxyburprocaine et un anti-inflamatoire non-steroide | |
| CA2667477C (fr) | Administration transdermique de derives polaires de ketoprofene | |
| NO330872B1 (no) | Utvortes preparat for behandling av pruritus | |
| KR20070059079A (ko) | 경피 페로스피론 투여용 의약적 조성물 | |
| CN109432061B (zh) | 含有布洛芬或其结构类似物的多层经皮给药系统 | |
| AU779624B2 (en) | Remedies for external use for allergic skin diseases | |
| JP4791682B2 (ja) | 痔疾患用治療剤 | |
| AU2004315561B2 (en) | External preparation for treating painful skin wound | |
| CA2499620C (fr) | Preparation externe contenant de l'acide acetylsalicylique pour inhiber la formation de cicatrices cheloidiennes | |
| WO2024125500A1 (fr) | Composition pharmaceutique topique et son utilisation en médecine | |
| WO2009154147A1 (fr) | Préparation analgésique/antiprurigineuse contenant de l'oxybuprocaïne pour application externe | |
| JP4313003B2 (ja) | 血液透析による皮膚疾患及び痒みの治療用外用剤 | |
| US20040258719A1 (en) | External preparation for treating dermatosis and pruritus due to hemodialysis | |
| JPH07223949A (ja) | 消炎鎮痛外用剤 | |
| ZA200606351B (en) | Remedy for external use for skin and mucosal injuries caused by viral infection | |
| JP2004137216A (ja) | ウイルス感染による皮膚・粘膜傷害症状に対する外用治療剤 | |
| ZA200606352B (en) | External preparation for treating painful skin wound | |
| WO2005077379A1 (fr) | Remede a usage externe pour lesions de la peau et des muqueuses causees par infection virale | |
| KR20060130651A (ko) | 통증이 있는 피부 창상의 치료용 외용제 | |
| JP2015003867A (ja) | 経皮吸収外用剤 | |
| MXPA06009275A (en) | External preparation for treating painful skin wound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |